DekaBank Deutsche Girozentrale Raises Stock Position in Pfizer Inc. (NYSE:PFE)

DekaBank Deutsche Girozentrale lifted its holdings in Pfizer Inc. (NYSE:PFE) by 1.1% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 7,398,373 shares of the biopharmaceutical company’s stock after acquiring an additional 83,564 shares during the period. DekaBank Deutsche Girozentrale’s holdings in Pfizer were worth $214,684,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in PFE. GHP Investment Advisors Inc. lifted its stake in shares of Pfizer by 8.8% in the 3rd quarter. GHP Investment Advisors Inc. now owns 13,697 shares of the biopharmaceutical company’s stock valued at $396,000 after purchasing an additional 1,108 shares during the last quarter. MCF Advisors LLC boosted its stake in Pfizer by 14.7% during the third quarter. MCF Advisors LLC now owns 18,408 shares of the biopharmaceutical company’s stock worth $533,000 after buying an additional 2,364 shares during the period. First Bank & Trust lifted its holdings in shares of Pfizer by 3.3% in the 3rd quarter. First Bank & Trust now owns 77,695 shares of the biopharmaceutical company’s stock worth $2,248,000 after acquiring an additional 2,459 shares during the last quarter. PFG Investments LLC raised its position in Pfizer by 4.7% in the 3rd quarter. PFG Investments LLC now owns 201,261 shares of the biopharmaceutical company’s stock worth $5,824,000 after purchasing an additional 9,121 shares during the period. Finally, Forsta AP Fonden boosted its position in shares of Pfizer by 10.8% during the third quarter. Forsta AP Fonden now owns 1,421,400 shares of the biopharmaceutical company’s stock valued at $41,135,000 after buying an additional 138,800 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research note on Wednesday. Daiwa Capital Markets upgraded shares of Pfizer from a “neutral” rating to an “outperform” rating and upped their price target for the stock from $28.00 to $34.00 in a report on Wednesday, August 7th. Citigroup initiated coverage on shares of Pfizer in a report on Friday. They set a “neutral” rating and a $30.00 price objective for the company. Daiwa America upgraded shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Finally, Barclays lifted their price target on shares of Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 31st. Eight research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Pfizer currently has an average rating of “Moderate Buy” and a consensus price target of $33.58.

Pfizer Trading Down 0.7 %

NYSE PFE opened at $28.45 on Friday. The firm has a market cap of $161.21 billion, a PE ratio of -474.17, a price-to-earnings-growth ratio of 1.01 and a beta of 0.67. Pfizer Inc. has a 52 week low of $25.20 and a 52 week high of $31.54. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.65. The company has a 50 day moving average price of $29.08 and a 200 day moving average price of $28.51.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, beating the consensus estimate of $0.46 by $0.14. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The firm had revenue of $13.28 billion during the quarter, compared to analyst estimates of $12.96 billion. During the same quarter in the prior year, the business posted $0.67 EPS. The business’s revenue for the quarter was up 2.1% compared to the same quarter last year. As a group, sell-side analysts forecast that Pfizer Inc. will post 2.67 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be paid a dividend of $0.42 per share. The ex-dividend date of this dividend is Friday, November 8th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.91%. Pfizer’s payout ratio is -2,800.00%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.